BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-04
185 industry Phase 2/3 trial readout(s) and 47 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2024-04-02 | FDA approval | approved | VANDA PHARMS INC VNDA | FANAPT | Approved 2024-04-02: FANAPT (NDA022192 SUPPL23) |
| 2024-04-03 | FDA approval | approved | EISAI INC | LENVIMA | Approved 2024-04-03: LENVIMA (NDA206947 SUPPL30) |
| 2024-04-03 | FDA approval | approved | ISTX | ZEVTERA | Approved 2024-04-03: ZEVTERA (NDA218275 ORIG1) |
| 2024-04-03 | FDA approval | approved | SUN PHARMA GLOBAL | ILUMYA | Approved 2024-04-03: ILUMYA (BLA761067 SUPPL18) |
| 2024-04-04 | FDA approval | approved | NOVA LABS LTD NVMI | XROMI | Approved 2024-04-04: XROMI (NDA216593 ORIG1) |
| 2024-04-05 | Complete response letter | complete response | Accord BioPharma Inc. | INTPS | CRL 2024-04-05: Accord BioPharma Inc. BLA 761147 (INTPS) |
| 2024-04-05 | FDA approval | approved | VIIV HLTHCARE | DOVATO | Approved 2024-04-05: DOVATO (NDA211994 SUPPL18) |
| 2024-04-05 | FDA approval | approved | VIIV HLTHCARE | DOVATO | Approved 2024-04-05: DOVATO (NDA211994 SUPPL19) |
| 2024-04-05 | FDA approval | approved | ASTRAZENECA AB AZN | FASENRA | Approved 2024-04-05: FASENRA (BLA761070 SUPPL20) |
| 2024-04-05 | FDA approval | approved | REGENERON PHARMACEUTICALS REGN | LIBTAYO | Approved 2024-04-05: LIBTAYO (BLA761097 SUPPL23) |
| 2024-04-05 | FDA approval | approved | DAIICHI SANKYO | ENHERTU | Approved 2024-04-05: ENHERTU (BLA761139 SUPPL28) |
| 2024-04-10 | FDA approval | approved | ELI LILLY AND CO LLY | RETEVMO | Approved 2024-04-10: RETEVMO (NDA218160 ORIG1) |
| 2024-04-12 | FDA AdCom | held | AdCom 2024-04-12: Oncologic Drugs Advisory Committee | ||
| 2024-04-12 | Complete response letter | complete response | Gan & Lee Pharmaceuticals | CRL 2024-04-12: Gan & Lee Pharmaceuticals BLA 761356 | |
| 2024-04-12 | FDA approval | approved | NOVARTIS NVS | ENTRESTO SPRINKLE | Approved 2024-04-12: ENTRESTO SPRINKLE (NDA218591 ORIG1) |
| 2024-04-12 | FDA approval | approved | NOVARTIS PHARMS CORP NVS | ENTRESTO | Approved 2024-04-12: ENTRESTO (NDA207620 SUPPL25) |
| 2024-04-16 | Complete response letter | approved since | Abeona Therapeutics, Inc. ABEO | CRL 2024-04-16: Abeona Therapeutics, Inc. BL 125807 | |
| 2024-04-16 | FDA approval | approved | ALVOTECH USA INC ALVO | SELARSDI | Approved 2024-04-16: SELARSDI (BLA761343 ORIG1) |
| 2024-04-17 | Complete response letter | complete response | Accord Healthcare Inc. | CRL 2024-04-17: Accord Healthcare Inc. NDA 218762 | |
| 2024-04-17 | FDA approval | approved | LUMICELL | LUMISIGHT | Approved 2024-04-17: LUMISIGHT (NDA214511 ORIG1) |
| 2024-04-18 | FDA approval | approved | HOFFMANN-LA ROCHE | ALECENSA | Approved 2024-04-18: ALECENSA (NDA208434 SUPPL15) |
| 2024-04-18 | FDA approval | approved | TAKEDA PHARMS USA TAK | ENTYVIO | Approved 2024-04-18: ENTYVIO (BLA761359 ORIG1) |
| 2024-04-19 | Complete response letter | complete response | Xbrane Biopharma AB | We have completed our review of this application, as amended | CRL 2024-04-19: Xbrane Biopharma AB BLA 761187 (We have completed our review of this application, as amended) |
| 2024-04-19 | Complete response letter | complete response | Dr. Reddy’s Laboratories SA | CRL 2024-04-19: Dr. Reddy’s Laboratories SA BLA 761376 | |
| 2024-04-19 | FDA approval | approved | BAUSCH AND LOMB INC BLCO | LUMIFY PRESERVATIVE FREE | Approved 2024-04-19: LUMIFY PRESERVATIVE FREE (NDA218424 ORIG1) |
| 2024-04-19 | FDA approval | approved | SCIENTURE SCNX | REZENOPY | Approved 2024-04-19: REZENOPY (NDA215487 ORIG1) |
| 2024-04-22 | FDA approval | approved | ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU | ANKTIVA | Approved 2024-04-22: ANKTIVA (BLA761336 ORIG1) |
| 2024-04-23 | FDA approval | approved | DAY ONE BIOPHARMS | OJEMDA | Approved 2024-04-23: OJEMDA (NDA218033 ORIG1) |
| 2024-04-23 | FDA approval | approved | DAY ONE BIOPHARMS | OJEMDA | Approved 2024-04-23: OJEMDA (NDA217700 ORIG1) |
| 2024-04-23 | FDA approval | approved | AAA USA INC | LUTATHERA | Approved 2024-04-23: LUTATHERA (NDA208700 SUPPL31) |
| 2024-04-24 | FDA approval | approved | GILEAD SCIENCES INC GILD | BIKTARVY | Approved 2024-04-24: BIKTARVY (NDA210251 SUPPL19) |
| 2024-04-24 | FDA approval | approved | NOVARTIS NVS | VIJOICE | Approved 2024-04-24: VIJOICE (NDA215039 SUPPL2) |
| 2024-04-24 | FDA approval | approved | NOVARTIS NVS | VIJOICE | Approved 2024-04-24: VIJOICE (NDA218466 ORIG1) |
| 2024-04-24 | FDA approval | approved | ALEMBIC THERAP | PIVYA | Approved 2024-04-24: PIVYA (NDA216483 ORIG1) |
| 2024-04-24 | FDA approval | approved | BAXTER HLTHCARE CORP BAX | CLINOLIPID 20% | Approved 2024-04-24: CLINOLIPID 20% (NDA204508 SUPPL22) |
| 2024-04-25 | FDA approval | approved | AMGEN INC AMGN | OTEZLA | Approved 2024-04-25: OTEZLA (NDA205437 SUPPL13) |
| 2024-04-25 | FDA approval | approved | ACCORD BIOPHARMA INC. | HERCESSI | Approved 2024-04-25: HERCESSI (BLA761346 ORIG1) |
| 2024-04-26 | FDA approval | approved | X4 PHARMS | XOLREMDI | Approved 2024-04-26: XOLREMDI (NDA218709 ORIG1) |
| 2024-04-26 | FDA approval | approved | ABBVIE ABBV | RINVOQ LQ | Approved 2024-04-26: RINVOQ LQ (NDA218347 ORIG1) |
| 2024-04-26 | FDA approval | approved | ABBVIE ABBV | RINVOQ | Approved 2024-04-26: RINVOQ (NDA211675 SUPPL22) |
| 2024-04-26 | FDA approval | approved | ABBVIE ABBV | RINVOQ | Approved 2024-04-26: RINVOQ (NDA211675 SUPPL21) |
| 2024-04-29 | FDA approval | approved | SEAGEN | TIVDAK | Approved 2024-04-29: TIVDAK (BLA761208 SUPPL7) |
| 2024-04-29 | FDA approval | approved | AURINIA AUPH | LUPKYNIS | Approved 2024-04-29: LUPKYNIS (NDA213716 SUPPL4) |
| 2024-04-30 | FDA approval | approved | NEUROCRINE NBIX | INGREZZA SPRINKLE | Approved 2024-04-30: INGREZZA SPRINKLE (NDA218390 ORIG1) |
| 2024-04-30 | FDA approval | approved | HOFFMAN-LA ROCHE | MIRCERA | Approved 2024-04-30: MIRCERA (BLA125164 SUPPL89) |
| 2024-04-30 | FDA approval | approved | BOEHRINGER INGELHEIM | CYLTEZO | Approved 2024-04-30: CYLTEZO (BLA761058 SUPPL26) |
| 2024-04-30 | FDA approval | approved | SUMITOMO PHARMA AM | MYFEMBREE | Approved 2024-04-30: MYFEMBREE (NDA214846 SUPPL7) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-04 est. | P2 | OncoSec Medical Incorporated | NCT03567720 Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | Triple Negative Breast Cancer | unknown | 65 |
| 2024-04 est. | P2 | Ascentage Pharma Group Inc. AAPG | NCT03883100 A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation | Chronic Myeloid Leukemia - Accelerated Phase | unknown | 23 |
| 2024-04 est. | P3 | Rigel Pharmaceuticals RIGL | NCT04138927 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | enrolling by invitation | 90 |
| 2024-04 est. | P2 | AC Immune SA ACIU | NCT04373616 A Study of ACI-24 in Adults With Down Syndrome | Down Syndrome | withdrawn | |
| 2024-04 est. | P2/P3 | Sinocelltech Ltd. | NCT04560894 SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | unknown | 405 |
| 2024-04 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05284994 TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer | Nonsmall-cell Lung Cancer | unknown | 160 |
| 2024-04 est. | P1/P2 | BiOneCure Therapeutics Inc. | NCT05320588 A Study in Patients With Advanced Cancers | Advanced Cancer; Advanced Solid Tumor; Cancer; Oncology | recruiting | 332 |
| 2024-04 est. | P2 | Abalonex, LLC | NCT06096415 Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury | Traumatic Brain Injury; Cerebral Edema | unknown | 45 |
| 2024-04-01 | P2 | Allarity Therapeutics ALLR | NCT03562832 Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP | Metastatic Breast Cancer | completed | 20 |
| 2024-04-01 | P3 | Chipscreen Biosciences, Ltd. | NCT04830813 Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer | Small Cell Lung Cancer | completed | 184 |
| 2024-04-01 | P2 | RyCarma Therapeutics, Inc. | NCT05122975 Treatment of an Inherited Ventricular Arrhythmia | Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 | terminated | 8 |
| 2024-04-01 | P1/P2 | Avenge Bio, Inc | NCT05538624 A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | Neoplasm, Ovarian; Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer; Adenocarcinoma Ovary; Se | terminated | 14 |
| 2024-04-01 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05628103 A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antip | Schizophrenia | completed | 101 |
| 2024-04-01 | P3 | TJ Biopharma Co., Ltd. | NCT05709093 A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With H | Myelodysplastic Syndromes(MDS) | terminated | 10 |
| 2024-04-01 | P3 | Novavax NVAX | NCT05973006 Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines | COVID-19 | completed | 400 |
| 2024-04-01 est. | P2 | CannaMore Biotechs | NCT06353828 Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients | Ulcerative Colitis | unknown | 45 |
| 2024-04-01 | P2 | Soterios Ltd | NCT06402630 A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moder | Alopecia Areata | completed | 158 |
| 2024-04-02 | P3 | Takeda TAK | NCT04075825 Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula | Crohn's Disease; Complex Perianal Fistula | completed | 150 |
| 2024-04-02 | P2 | Redx Pharma Ltd | NCT04907539 A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorecta | Colorectal Cancer | completed | 25 |
| 2024-04-02 | P2 | Hope Biosciences Research Foundation | NCT05126563 Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome | Post COVID-19 Syndrome | completed | 79 |
| 2024-04-02 | P3 | Janssen Research & Development, LLC | NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | Colitis, Ulcerative | active not recruiting | 418 |
| 2024-04-02 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT05650554 Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older | Influenza Immunization | completed | 682 |
| 2024-04-02 | P3 | Novartis Pharmaceuticals NVS | NCT05888103 Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. | Primary Hypercholesterolemia or Mixed Dyslipidemia | completed | 207 |
| 2024-04-03 | P3 | Novartis Pharmaceuticals NVS | NCT04732117 Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis | Non-radiographic Axial Spondyloarthritis | completed | 137 |
| 2024-04-03 | P2/P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05149807 Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer | Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophag | terminated | 81 |
| 2024-04-03 | P3 | AO GENERIUM | NCT05492409 Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients | Idiopathic Thrombocytopenic Purpura | completed | 160 |
| 2024-04-03 | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT05983445 Safety & Efffficacy of Genakumab in Patients With Frequent Flares | Acute Gout Arthritis | completed | 313 |
| 2024-04-03 | P3 | GlaxoSmithKline | NCT06868654 China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in | Multiple Myeloma | active not recruiting | 72 |
| 2024-04-03 | P3 | GlaxoSmithKline | NCT06868667 Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone | Multiple Myeloma | active not recruiting | 24 |
| 2024-04-04 | P1/P2 | Bristol-Myers Squibb BMY | NCT03110107 First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | Advanced Cancer | terminated | 376 |
| 2024-04-04 | P3 | Janssen Research & Development, LLC | NCT03901963 A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minima | Multiple Myeloma | completed | 200 |
| 2024-04-04 | P1/P2 | Sanofi SNY | NCT04418661 Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies | Metastatic Neoplasm | terminated | 65 |
| 2024-04-04 | P1/P2 | Istari Oncology, Inc. | NCT04690699 LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors | Solid Tumor; Bladder Cancer; Non-muscle-invasive Bladder Cancer | terminated | 4 |
| 2024-04-04 | P1/P2 | Intellia Therapeutics NTLA | NCT05120830 NTLA-2002 in Adults With Hereditary Angioedema (HAE) | Hereditary Angioedema | active not recruiting | 37 |
| 2024-04-04 | P2 | Imugene Limited | NCT05311176 A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON | Gastric Cancer; Cancer of Stomach; Gastric Adenocarcinoma; Stomach Cancer; Stomach Adenocarcinoma; G | terminated | 7 |
| 2024-04-04 | P1/P2 | AskBio France, SAS, a subsidiary of AskBio Inc. | NCT05541627 A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease | Huntington Disease | active not recruiting | 5 |
| 2024-04-04 | P2 | AstraZeneca AZN | NCT05638737 A Study in Participants With Non-cirrhotic NASH With Fibrosis | Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | completed | 112 |
| 2024-04-05 | P3 | Sun Pharmaceutical Industries Limited | NCT03897075 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | Chronic Plaque Psoriasis; Moderate to Severe Nail Psoriasis | completed | 99 |
| 2024-04-05 | P2 | Gyroscope Therapeutics Limited | NCT04437368 EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 | Dry Age-related Macular Degeneration | terminated | 98 |
| 2024-04-05 | P3 | Teva Pharmaceuticals USA | NCT04976192 Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria | Chronic Urticaria | completed | 608 |
| 2024-04-05 | P2 | Aviceda Therapeutics, Inc. | NCT06181227 A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema | Diabetic Macular Edema; Diabetic Retinopathy | terminated | 21 |
| 2024-04-06 | P3 | Merck Sharp & Dohme LLC MRK | NCT04772534 Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) | Papillomavirus Infections | completed | 314 |
| 2024-04-06 est. | P3 | Sobi, Inc. | NCT05046327 Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months | Immune Thrombocytopenia | withdrawn | |
| 2024-04-06 | P3 | Vanda Pharmaceuticals VNDA | NCT05903924 Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness | Motion Sickness | completed | 316 |
| 2024-04-08 | P3 | UCB BIOSCIENCES GmbH | NCT01550003 Pediatric Arthritis Study of Certolizumab Pegol | Polyarticular-course Juvenile Idiopathic Arthritis (JIA) | completed | 193 |
| 2024-04-08 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT03179436 Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | Advanced Solid Tumors | completed | 415 |
| 2024-04-08 | P3 | AB2 Bio Ltd. | NCT03512314 Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension | XIAP Deficiency; NLRC4-MAS | completed | 11 |
| 2024-04-08 | P2 | Sun Pharma Advanced Research Company Limited | NCT03655236 PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 | Early Parkinson Disease | terminated | 513 |
| 2024-04-08 | P3 | Corcept Therapeutics CORT | NCT03697109 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome | Cushing Syndrome | completed | 152 |
| 2024-04-08 | P3 | CSL Behring | NCT03744910 Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients | Antibody-mediated Rejection | terminated | 194 |
| 2024-04-08 | P2 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05221502 Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB | Pulmonary TB | completed | 122 |
| 2024-04-08 | P1/P2 | AnnJi Pharmaceutical Co., Ltd. | NCT05517603 A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients | Spinal and Bulbar Muscular Atrophy; Kennedy's Disease | completed | 25 |
| 2024-04-08 | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT07239765 A Study to Evaluate the Safety, Efficacy, and PPK of ABCD in Patients With IMD | Invasive Mold Disease | completed | 67 |
| 2024-04-09 | P3 | Amgen AMGN | NCT04540497 A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease | IgG4 Related Disease | active not recruiting | 135 |
| 2024-04-09 | P1/P2 | Kronos Bio | NCT05028751 A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia | terminated | 24 |
| 2024-04-10 | P2 | Gedeon Richter Plc. | NCT05322096 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome | Prader-Willi Syndrome | completed | 39 |
| 2024-04-10 | P3 | Eli Lilly and Company LLY | NCT05362058 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time | Diabetes; Type 2 Diabetes | completed | 928 |
| 2024-04-10 est. | P1/P2 | Biotheus Inc. | NCT05867771 A Study of PM1022 in Patients With Advanced Tumors | Advanced Tumors | unknown | 200 |
| 2024-04-11 | P2 | US Oncology Research | NCT02187991 Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | Breast Cancer; Breast Carcinoma; Breast Tumors; Malignant Neoplasm of Breast | completed | 169 |
| 2024-04-11 | P3 | Medeor Therapeutics, Inc. | NCT03363945 Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants | Kidney Transplant Rejection | completed | 30 |
| 2024-04-11 | P1/P2 | UCB Biopharma SRL | NCT04393298 A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Advanced Solid Tumors | completed | 93 |
| 2024-04-11 | P3 | GlaxoSmithKline | NCT04718103 A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype | Asthma | completed | 397 |
| 2024-04-11 | P3 | Agios Pharmaceuticals, Inc. AGIO | NCT04770779 A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | active not recruiting | 258 |
| 2024-04-11 | P3 | Takeda TAK | NCT04940624 A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome | Dravet Syndrome (DS) | completed | 144 |
| 2024-04-11 | P2 | Incyte Corporation INCY | NCT04949191 The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | Advanced Malignancies | terminated | 10 |
| 2024-04-11 | P3 | Gilead Sciences GILD | NCT05079230 Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia | Acute Myeloid Leukemia | terminated | 378 |
| 2024-04-11 | P2 | Aelis Farma | NCT05322941 Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) | Marijuana Abuse | completed | 333 |
| 2024-04-11 | P3 | Novo Nordisk A/S NVO | NCT05365217 A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B | Haemophilia B | completed | 30 |
| 2024-04-11 | P1/P2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | NCT05762471 Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus | Overweight or Obesity; Type2 Diabetes Mellitus | completed | 142 |
| 2024-04-12 | P2 | NFL Biosciences SAS | NCT04571216 Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy | Smoking Cessation; Nicotine Dependence | completed | 318 |
| 2024-04-12 | P2 | AstraZeneca AZN | NCT05061134 A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition | Melanoma | active not recruiting | 194 |
| 2024-04-12 | P3 | Intra-Cellular Therapies, Inc. | NCT05061706 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Major Depressive Disorder | completed | 480 |
| 2024-04-12 | P1/P2 | Mustang Bio MBIO | NCT05360238 Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Follicular B-cell Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma Recurrent; Mantle Cell Lymphoma Refra | terminated | 20 |
| 2024-04-12 | P2 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT05752461 SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty | Prevention of Venous Thromboembolism After Knee Arthroplasty | completed | 353 |
| 2024-04-12 | P3 | Jiangsu Simcere Pharmaceutical Co., Ltd. | NCT06010693 A Study of Daridorexant in Chinese Patients With Insomnia Disorder | Insomnia Disorder | completed | 206 |
| 2024-04-12 | P3 | Beijing Minhai Biotechnology Co., Ltd | NCT06752174 A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis | Poliomyelitis | completed | 300 |
| 2024-04-14 est. | P3 | China National Biotec Group Company Limited | NCT05669625 A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine | Varicella | unknown | 12440 |
| 2024-04-15 | P3 | Janssen Research & Development, LLC | NCT03390504 A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Fac | Urothelial Cancer | active not recruiting | 629 |
| 2024-04-15 | P3 | Merck Sharp & Dohme LLC MRK | NCT04195750 A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | Carcinoma, Renal Cell | active not recruiting | 755 |
| 2024-04-15 | P3 | Incyte Corporation INCY | NCT04472429 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | Squamous Cell Carcinoma of the Anal Canal | completed | 308 |
| 2024-04-15 est. | P1/P2 | OncoResponse, Inc. | NCT05094804 A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Non Small Cell Lu | unknown | 172 |
| 2024-04-15 | P2 | Verrica Pharmaceuticals Inc. VRCA | NCT05188729 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma | Basal Cell Carcinoma; Skin Cancer; Cancer of the Skin, Basal Cell; Cancer of the Skin; Carcinoma | completed | 92 |
| 2024-04-15 est. | P2 | OncXerna Theraputics, Inc. | NCT05453825 A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | Colorectal Cancer; Triple Negative Breast Cancer; Gastric Cancer; Ovarian Cancer | unknown | 180 |
| 2024-04-15 | P1/P2 | Enlivex Therapeutics RDO Ltd. ENLV | NCT05581719 A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | Solid Tumor; Peritoneal Metastases; Peritoneal Cancer | terminated | 14 |
| 2024-04-15 | P2 | Binhui Biopharmaceutical Co., Ltd. | NCT05648006 First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | Advanced Colorectal Carcinoma | terminated | 7 |
| 2024-04-15 | P3 | MediBeacon | NCT05777174 Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring | Kidney Diseases; Kidney Injury; Kidney Failure | completed | 149 |
| 2024-04-15 | P2 | Shionogi | NCT05925114 Safety and Efficacy Study of S-309309 in Obese Adults | Obesity | completed | 365 |
| 2024-04-16 | P3 | Zambon SpA | NCT03657342 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) | Bronchiolitis Obliterans; Chronic Rejection of Lung Transplant; Lung Transplant Rejection; Lung Tran | completed | 62 |
| 2024-04-16 | P2 | Crestone, Inc | NCT04781387 Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection | Clostridioides Difficile Infection | completed | 43 |
| 2024-04-16 | P3 | AstraZeneca AZN | NCT05006573 Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis | terminated | 100 |
| 2024-04-16 | P2/P3 | Shanghai Xinzhi BioMed Co., Ltd. | NCT05203679 Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug | Hemophilia B | active not recruiting | 32 |
| 2024-04-16 | P2/P3 | Boehringer Ingelheim | NCT05218499 Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | Liposarcoma, Dedifferentiated | completed | 400 |
| 2024-04-16 | P3 | Ferring Pharmaceuticals | NCT05263388 A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation | Infertility | completed | 302 |
| 2024-04-16 | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05496426 A Study of KL130008 in Adults With Severe Alopecia Areata | Alopecia Areata | terminated | 114 |
| 2024-04-16 | P3 | Colgate Palmolive CL | NCT06244303 Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis. | Gingivitis; Plaque | completed | 82 |
| 2024-04-17 | P2/P3 | Seagen Inc. | NCT04499924 Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma | completed | 17 |
| 2024-04-17 | P2/P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT04856787 A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC | Metastatic Colorectal Cancer (mCRC) | terminated | 62 |
| 2024-04-17 | P2 | Hoffmann-La Roche | NCT05151744 A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema | Diabetic Macular Edema | completed | 187 |
| 2024-04-17 | P2 | Huahui Health | NCT05734807 A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia | Chronic HBV Infection | completed | 74 |
| 2024-04-18 | P2/P3 | Shire | NCT02412787 Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094 | Hunter Syndrome | completed | 56 |
| 2024-04-18 | P2 | Ionis Pharmaceuticals, Inc. IONS | NCT03815825 GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular D | Macular Degeneration; Geographic Atrophy | completed | 332 |
| 2024-04-18 | P2 | AbbVie ABBV | NCT04309474 A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | Acute Ischemic Stroke | completed | 121 |
| 2024-04-18 | P3 | Novo Nordisk A/S NVO | NCT05564117 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range | Overweight; Obesity | completed | 307 |
| 2024-04-18 | P2 | argenx ARGX | NCT05633407 Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | Postural Orthostatic Tachycardia Syndrome | completed | 53 |
| 2024-04-18 | P3 | Merck Sharp & Dohme LLC MRK | NCT05763823 A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipi | Cytomegalovirus Infection | completed | 120 |
| 2024-04-18 est. | P2 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | NCT06277128 A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. | Hyperkalemia | unknown | 140 |
| 2024-04-19 | P3 | Exelixis EXEL | NCT04446117 Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | Metastatic Prostate Cancer; Prostate Adenocarcinoma | active not recruiting | 575 |
| 2024-04-19 | P2/P3 | Hoffmann-La Roche | NCT04619797 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin | Non-small Cell Lung Cancer (NSCLC) | completed | 542 |
| 2024-04-19 | P2 | AstraZeneca AZN | NCT05364931 A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis | Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | completed | 54 |
| 2024-04-19 | P2 | Azafaros B.V. | NCT05758922 Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Typ | GM2 Gangliosidosis; Niemann-Pick Disease, Type C | completed | 13 |
| 2024-04-19 | P3 | Alvotech Swiss AG ALVO | NCT05986786 Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease | Chorioretinal Vascular Disease | completed | 35 |
| 2024-04-20 | P3 | Annexon, Inc. ANNX | NCT04701164 Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome | Guillain-Barre Syndrome | completed | 242 |
| 2024-04-20 est. | P2 | Incyte Biosciences International Sàrl INCY | NCT05359692 INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma; Advanced Malignancies; Recurrent Head and Neck Squ | withdrawn | |
| 2024-04-20 est. | P1/P2 | Egymedicalpedia | NCT06239324 Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser | Alopecia Areata | unknown | 70 |
| 2024-04-22 | P3 | Humacyte, Inc. HUMA | NCT03183245 Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis | Renal Failure; End Stage Renal Disease; Hemodialysis; Vascular Access | completed | 242 |
| 2024-04-22 | P3 | Taiho Oncology, Inc. | NCT04093362 Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements | terminated | 10 |
| 2024-04-22 est. | P2 | GlaxoSmithKline | NCT04151225 Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease | Crohns Disease; Crohn's Disease | withdrawn | |
| 2024-04-22 | P2 | Aura Biosciences AURA | NCT04417530 Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal M | Uveal Melanoma; Ocular Melanoma; Choroidal Melanoma | completed | 22 |
| 2024-04-22 | P1/P2 | S.Biomedics Co., Ltd. | NCT04661644 Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia | Critical Limb Ischemia | completed | 20 |
| 2024-04-22 | P1/P2 | Gamida Cell ltd | NCT05296525 Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL | Non-Hodgkin Lymphoma | terminated | 13 |
| 2024-04-22 | P1/P2 | iOx Therapeutics | NCT05709821 IMM60 and Pembrolizumab in Melanoma and NSCLC | Non-small Cell Lung Cancer; Melanoma | terminated | 1 |
| 2024-04-22 | P2/P3 | Cara Therapeutics, Inc. | NCT05978063 Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica | Pruritus; Notalgia Paresthetica | terminated | 214 |
| 2024-04-23 | P1/P2 | UCB Biopharma SRL | NCT04643457 A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis | Atopic Dermatitis | completed | 107 |
| 2024-04-23 | P2 | Boehringer Ingelheim | NCT05282121 A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steato | Liver Diseases; Hypertension, Portal | terminated | 90 |
| 2024-04-23 | P3 | Handok Inc. | NCT05504239 Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin | Type 2 Diabetes | completed | 235 |
| 2024-04-23 | P3 | UCB Biopharma SRL | NCT05681715 A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG) | Generalized Myasthenia Gravis | completed | 62 |
| 2024-04-23 | P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05702788 Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) | COVID-19; Pneumonia | withdrawn | |
| 2024-04-24 | P2 | Xoft, Inc. | NCT04681677 Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab | Glioblastoma; Recurrent Glioblastoma; GBM; Recurrent GBM | terminated | 12 |
| 2024-04-24 | P1/P2 | Endogena Therapeutics, Inc | NCT05392751 Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa | Retinitis Pigmentosa; Retinitis Pigmentosa Syndrome | terminated | 14 |
| 2024-04-24 | P3 | Eli Lilly and Company LLY | NCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) | Alzheimer's Disease | completed | 1667 |
| 2024-04-24 | P2 | RMW Testing | NCT06003049 A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD | COPD | completed | 40 |
| 2024-04-25 | P1/P2 | VegaVect, Inc. | NCT02317887 Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis | Retinoschisis; X-Linked | completed | 12 |
| 2024-04-25 | P2 | Jounce Therapeutics, Inc. | NCT04549025 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-contai | NSCLC | terminated | 69 |
| 2024-04-25 | P3 | Takeda TAK | NCT04842643 An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease | Primary Immunodeficiency Disease | completed | 12 |
| 2024-04-25 | P2 | Gilead Sciences GILD | NCT04892446 Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | terminated | 36 |
| 2024-04-25 est. | P3 | Incyte Corporation INCY | NCT05219864 Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 | Hand Eczema | withdrawn | |
| 2024-04-25 est. | P3 | Incyte Corporation INCY | NCT05233410 Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 | Chronic Hand Eczema (CHE) | withdrawn | |
| 2024-04-25 | P2 | Novartis Pharmaceuticals NVS | NCT05507437 Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury | Acute Kidney Injury Due to Sepsis | completed | 20 |
| 2024-04-25 | P3 | Atea Pharmaceuticals, Inc. AVIR | NCT05629962 SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection); COVID-19 | completed | 2285 |
| 2024-04-25 | P3 | Novartis Pharmaceuticals NVS | NCT05795153 A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1 | Chronic Spontaneous Urticaria | completed | 144 |
| 2024-04-25 | P2 | Seqirus | NCT05874713 Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults | Influenza, Human; Infections; Respiratory Tract Infections; Virus Diseases; Infection Viral | completed | 480 |
| 2024-04-26 | P1/P2 | Bristol-Myers Squibb BMY | NCT03400332 A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | Cancer; Melanoma | completed | 281 |
| 2024-04-26 | P2 | Novartis Pharmaceuticals NVS | NCT04390763 Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocar | Metastatic Pancreatic Ductal Adenocarcinoma | terminated | 164 |
| 2024-04-26 | P3 | Hoffmann-La Roche | NCT04732286 A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma | Carcinoma, Hepatocellular | terminated | 100 |
| 2024-04-26 | P2 | Boehringer Ingelheim | NCT04876391 A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial | Hidradenitis Suppurativa | completed | 45 |
| 2024-04-26 | P3 | Sedana Medical | NCT05312385 Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive C | Sedation | completed | 277 |
| 2024-04-26 | P3 | Harbour BioMed (Guangzhou) Co. Ltd. | NCT05332210 Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis | Myasthenia Gravis | completed | 111 |
| 2024-04-26 | P2 | Eisai Co., Ltd. | NCT05594589 A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder | Sleep Initiation and Maintenance Disorders | completed | 65 |
| 2024-04-26 | P2 | Palatin Technologies, Inc PTN | NCT05709444 A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease | Kidney Disease | completed | 16 |
| 2024-04-26 | P2 | Novartis Pharmaceuticals NVS | NCT05764265 Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants | Pulmonary Arterial Hypertension | terminated | 31 |
| 2024-04-26 | P1/P2 | Inmagene LLC | NCT05984784 A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) | Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis; AD | terminated | 13 |
| 2024-04-26 | P2 | SNLD, Ltd. | NCT06212089 Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease | Parkinson Disease | completed | 12 |
| 2024-04-27 est. | P2 | 60P Australia Pty Ltd | NCT05947812 A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mil | COVID 19 Disease; Mild to Moderate COVID 19 Disease; SARS-CoV-2; Infectious Disease; Severe Acute Re | unknown | 148 |
| 2024-04-29 | P3 | AstraZeneca AZN | NCT03732677 Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC | Muscle Invasive Bladder Cancer | active not recruiting | 1063 |
| 2024-04-29 | P1/P2 | Arvinas Inc. ARVN | NCT03888612 Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer | Prostate Cancer Metastatic | completed | 248 |
| 2024-04-29 | P2 | RECORDATI GROUP | NCT04276558 REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients | Neurotrophic Keratitis | completed | 108 |
| 2024-04-29 | P2 | Takeda TAK | NCT04278924 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | completed | 41 |
| 2024-04-29 | P1/P2 | Impact Therapeutics, Inc. IBO | NCT04434482 IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Advanced Solid Tumours; Small Cell Lung Cancer | completed | 59 |
| 2024-04-29 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04895345 A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | completed | 25 |
| 2024-04-29 | P3 | Arrowhead Pharmaceuticals ARWR | NCT05089084 Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) | Familial Chylomicronemia | completed | 75 |
| 2024-04-29 | P1/P2 | Hookipa Biotech GmbH | NCT05553639 HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer | Prostate Cancer Metastatic | terminated | 12 |
| 2024-04-29 | P2/P3 | Pfizer PFE | NCT05732454 A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or | Atopic Dermatitis; Atopic Dermatitis, Unspecified; Eczema; Eczema, Atopic | terminated | 58 |
| 2024-04-30 | P3 | Celgene | NCT01476787 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma | Follicular Lymphoma | completed | 1030 |
| 2024-04-30 | P1/P2 | Takeda TAK | NCT01506141 An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants Wit | Hunter Syndrome | completed | 15 |
| 2024-04-30 est. | P1/P2 | Stemedica Cell Technologies, Inc. | NCT01771679 Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging | Chronic Effect of Ultraviolet Radiation on Photoaged Skin; Dermatologic Disorders | unknown | 29 |
| 2024-04-30 | P3 | ACADIA Pharmaceuticals Inc. ACAD | NCT03121586 Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia | Schizophrenia | terminated | 995 |
| 2024-04-30 | P2 | Incyte Corporation INCY | NCT03235544 A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor | Lymphoma | completed | 162 |
| 2024-04-30 | P2 | IVIEW Therapeutics Inc. | NCT03749317 Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis | Adenoviral Conjunctivitis | completed | 135 |
| 2024-04-30 | P1/P2 | HELP Therapeutics Co., Ltd. | NCT03763136 Treating Heart Failure With hPSC-CMs | Heart Failure | completed | 20 |
| 2024-04-30 est. | P1/P2 | CAS Lamvac Biotech Co., Ltd. | NCT04165590 Plasmodium Immunotherapy for Advanced Malignant Solid Tumors | Advanced Malignant Solid Tumor | unknown | 60 |
| 2024-04-30 | P1/P2 | Hutchmed HCM | NCT04579757 Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Metastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Ca | terminated | 87 |
| 2024-04-30 | P1/P2 | InventisBio Co., Ltd | NCT04585035 Study to Evaluate D-1553 in Subjects With Solid Tumors | Solid Tumor, Adult; NSCLC; CRC | unknown | 180 |
| 2024-04-30 | P2 | OSE Immunotherapeutics | NCT04882007 Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis | Ulcerative Colitis | completed | 136 |
| 2024-04-30 | P2 | Janssen Research & Development, LLC | NCT04882878 A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | completed | 228 |
| 2024-04-30 | P3 | Boehringer Ingelheim | NCT05065190 A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis | Lung Diseases, Interstitial | completed | 81 |
| 2024-04-30 | P2/P3 | Acticor Biotech | NCT05070260 ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo | Acute Ischemic Stroke | completed | 438 |
| 2024-04-30 est. | P3 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT05149326 KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma. | Advanced Pancreatic Ductal Adenocarcinoma | unknown | 408 |
| 2024-04-30 est. | P1/P2 | Shanghai YingLi Pharmaceutical Co. Ltd. | NCT05173805 Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation | Advanced Solid Tumor | unknown | 150 |
| 2024-04-30 est. | P1/P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT05207787 Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors | Solid Tumor | unknown | 306 |
| 2024-04-30 est. | P1/P2 | Phoenicis Therapeutics | NCT05529134 Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene | Dystrophic Epidermolysis Bullosa | unknown | 8 |
| 2024-04-30 | P1/P2 | Medikine, Inc. | NCT05716295 A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | terminated | 26 |
| 2024-04-30 | P2 | Wuhan Createrna Science and Technology Co., Ltd | NCT06050226 A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal Nocturnal Hemoglobinuria | completed | 34 |
| 2024-04-30 | P3 | Rose Research Center, LLC | NCT06088862 Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT | Smoking Cessation; Harm Reduction | terminated | 4 |
| 2024-04-30 | P3 | CanSino Biologics Inc. | NCT06120751 A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over | Tetanus | completed | 1000 |
| 2024-04-30 | P2 | Halia Therapeutics, Inc. | NCT06241742 Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction | Pain | completed | 81 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.